FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 163 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate... February 12, 2025 Double Mastectomies Do Not Lower Risk Of Death For Breast Cancer... January 22, 2020 FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma August 24, 2020 Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age October 26, 2020 Load more HOT NEWS Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For... Young Boy Wears Shirt That Says ‘I Will Be Your Friend’... FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer Study Shows that Disrupted Gut Bacteria May Contribute to the Spread...
